As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part…
| Price | $5.30 |
|---|---|
| Market cap | $219.4M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NASDAQ |
| 52-week range | 4.48-13.22 |
| Beta | 1.16 |
Explore RXST's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.